Live IPO - Koligo Therapeutics Ltd.

Koligo Therapeutics Ltd (ASX: KOL) was incorporated on 27 June 2018 for the primary purpose of acquiring Koligo Therapeutics, Inc (Koligo) a US biotechnology company focused on the development and commercialisation of a range of cell therapy, three-dimensional (3D) bioprinted tissue and other regenerative medicine products for serious unmet medical needs.

Koligo has successfully commercialised and has recently commenced selling its first cell therapy transplant product, Kyslecel™, for the treatment of chronic pancreatitis patients, in the United States.  Kyslecel™ is used in the treatment of patients suffering from chronic or acute recurrent pancreatitis, a debilitating and painful condition with few effective treatment options. Since 14 months ago, when sales commenced to a limited number of initial hospital customers, Koligo has generated revenues of approximately $1,600,000 from sales of this product.  

Koligo is currently developing Kyslecel™ v2.0, an improved formulation that is intended to extend the product’s shelf life and thus expand Koligo’s geographic reach. Koligo also seeks to develop and commercialize a range of other transformative cell therapies for a range of indications, including type 1 diabetes, and other pancreatic diseases; as well as 3D printed pre-vascularised cell/tissue structures for multiple indications, including liver failure, neurological diseases, metabolic disorders, and genetic disorders. Oversimplifying somewhat, pre-vascularised cell/tissue structures are 3D bio-printed for transplantation into humans with blood vessels already embedded in the tissue.

• Pay by: April 5

• List Price: $0.20

• Minimum Investment: $2,000

• Maximum Investment: $10,000

• Prospectus
  

Closed

Live IPO - Mediland Pharm Ltd.

Mediland Pharm Ltd (ASX: MPH) was founded as a Sydney based family business in 2002 and has grown to become a market leading retailer servicing the Chinese inbound tourism sector in Australia. With three strategically located retail outlets in Sydney, Melbourne and Surfers Paradise, the Company’s retail experience and merchandising strategies are designed to capture a significant share of the spending of the various tour groups.

By partnering with major travel agents and wholesale tour operators who are all Chinese Government certified under the Approved Destination Status (ADS) scheme, Mediland Pharm has grown strongly over the years, consistent with the growth of inbound tourist numbers from China and increasing level of expenditure by Chinese tourists.

• Pay by: 11 February 19

• List Price: $0.20

• Minimum Investment: $2,000

• Maximum Investment: $10,000

• Prospectus
  

Closed

Live IPO - HeraMED Limited.

HeraMED (ASX:HMD) was incorporated in 2011 in Israel as a technology start-up developing innovative, connected pregnancy monitoring solutions.Its first commercial product, HeraBEAT™ is a medical-grade, clinically validated fetal heart rate monitor mainly for home use.

Today, fetal heart monitoring is a standard part of every pregnancy check-up, but current technologies are expensive, bulky, limited and designed for professional use only. The result is that pregnancy monitoring almost always requires a clinical setting, a nurse or doctor to conduct the measurement and the careful attention of a trained obstetrician-gynaecologist for a subjective, time-consuming, visual interpretation of FHR pattern recognition and assessment.

HeraMED’s aim is to become a world leader in innovative, accessible, technology-driven products which change the way practitioners and expectant mothers approach and monitor the miracle of pregnancy.

• Pay by: 2 November 18

• List Price: $0.20

• Minimum Investment: $2,000

• Maximum Investment: $5,000

• Prospectus
  

Closed.